Veraxa Biotech (NASDAQ:VRXA) Stock Price Up 15.6% – What’s Next?

Veraxa Biotech Holding AG (NASDAQ:VRXA)’s share price rose 15.6% on Friday. The company traded as high as $1.4089 and last traded at $1.26. Approximately 1,859,788 shares traded hands during mid-day trading, an increase of 1,388% from the average session volume of 124,995 shares. The stock had previously closed at $1.09.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Veraxa Biotech from a “sell” rating to a “hold” rating in a research report on Monday, August 31st.

Veraxa Biotech Stock Performance

Insiders Place Their Bets

In other news, Director Oliver Baumann bought 50,000 shares of Veraxa Biotech stock in a transaction dated Thursday, August 27th. The shares were acquired at an average price of $1.50 per share, with a total value of $75,000.00. Following the completion of the purchase, the director owned 5,773,618 shares in the company, valued at $8,660,427. The trade was a 0.87% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Veraxa Biotech Company Profile

VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation. Its product pipeline includes drug candidates such as ADCs and BITACs, with some in clinical development, and it provides partnership models for collaborative development from target identification to antibody and ADC creation.